Sphera Funds Management Ltd. 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Sphera Funds Management Ltd. disclosed 97 US equity positions worth $698.8m in its Q2 2026 13F filing. The largest position was TEVA at 7.3% of the reported book, followed by MLYS and TSEM. Against the Q1 2026 filing, it opened 7 new positions, added to 24 and reduced 11 among the top 50 holdings.
What did Sphera Funds Management Ltd. own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 7.3% | $50.8m | 1,500,082 | 32% | added |
| 2 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 5.7% | $39.7m | 1,469,971 | 10% | added |
| 3 | TSEM TOWER SEMICONDUCTOR LTD | Technology | 4.0% | $28.2m | 108,265 | -26% | reduced |
| 4 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.2% | $22.2m | 1,014,606 | 40% | added |
| 5 | BIIB BIOGEN INC | Healthcare | 3.0% | $20.9m | 96,626 | 4% | added |
| 6 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.8% | $19.6m | 588,494 | -27% | reduced |
| 7 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 2.7% | $18.8m | 328,550 | 135% | added |
| 8 | CYTK CYTOKINETICS INC | Healthcare | 2.7% | $18.7m | 219,987 | 452% | added |
| 9 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.6% | $18.3m | 245,346 | 0% | held |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.5% | $17.8m | 459,340 | 10% | added |
| 11 | NVMI NOVA LTD | Technology | 2.0% | $13.7m | 25,169 | -53% | reduced |
| 12 | INSM INSMED INC | Healthcare | 1.8% | $12.7m | 118,800 | – | new |
| 13 | MAZE MAZE THERAPEUTICS INC | Healthcare | 1.8% | $12.5m | 417,564 | 84% | added |
| 14 | AZN ASTRAZENECA PLC | Healthcare | 1.7% | $11.9m | 62,530 | 0% | held |
| 15 | SNY SANOFI SA | Healthcare | 1.6% | $11.5m | 269,515 | 0% | held |
| 16 | HELP CYBIN INC | 1.5% | $10.7m | 1,620,753 | 64% | added | |
| 17 | LLY ELI LILLY & CO | Healthcare | 1.4% | $9.6m | 8,040 | -11% | reduced |
| 18 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.3% | $9.4m | 17,419 | 93% | added |
| 19 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.3% | $9.3m | 499,029 | -13% | reduced |
| 20 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 1.3% | $9.0m | 356,534 | 39% | added |
| 21 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.3% | $9.0m | 240,868 | -1% | reduced |
| 22 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.3% | $8.9m | 80,400 | – | new |
| 23 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.2% | $8.2m | 752,983 | 40% | added |
| 24 | LRCX LAM RESEARCH CORP | Technology | 1.1% | $8.0m | 18,470 | – | new |
| 25 | AMAT APPLIED MATLS INC | Technology | 1.1% | $8.0m | 11,040 | – | new |
| 26 | TNGX TANGO THERAPEUTICS INC | Healthcare | 1.1% | $7.9m | 254,250 | -26% | reduced |
| 27 | NVS NOVARTIS AG | Healthcare | 1.1% | $7.8m | 50,000 | 35% | added |
| 28 | SOLAREDGE TECHNOLOGIES INC | 1.1% | $7.7m | 4,000,000 | 0% | held | |
| 29 | VOR VOR BIOPHARMA INC | Healthcare | 1.1% | $7.7m | 416,417 | 29% | added |
| 30 | ABBV ABBVIE INC | Healthcare | 1.1% | $7.6m | 30,256 | 0% | held |
| 31 | MRK MERCK & CO INC | Healthcare | 1.1% | $7.5m | 58,600 | 21% | added |
| 32 | JNJ JOHNSON & JOHNSON | Healthcare | 1.0% | $7.3m | 28,831 | 0% | held |
| 33 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.0% | $7.3m | 196,408 | – | new |
| 34 | IMTX IMMATICS N.V | Healthcare | 1.0% | $7.3m | 720,057 | 3% | added |
| 35 | NVCT NUVECTIS PHARMA INC | 1.0% | $7.0m | 382,945 | – | new | |
| 36 | PFE PFIZER INC | Healthcare | 1.0% | $6.9m | 286,000 | 54% | added |
| 37 | HRMY HARMONY BIOSCIENCES HLDGS IN | Healthcare | 0.9% | $6.4m | 176,663 | – | new |
| 38 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.9% | $6.3m | 105,000 | -17% | reduced |
| 39 | CLYM CLIMB BIO INC | Healthcare | 0.9% | $6.3m | 483,747 | 15% | added |
| 40 | ZBIO ZENAS BIOPHARMA INC | 0.8% | $5.9m | 230,834 | 8% | added | |
| 41 | NVO NOVO-NORDISK A S | Healthcare | 0.8% | $5.8m | 120,677 | 0% | held |
| 42 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.8% | $5.7m | 112,765 | -26% | reduced |
| 43 | PRLD PRELUDE THERAPEUTICS INC | 0.8% | $5.4m | 1,019,832 | 83% | added | |
| 44 | GSK GSK PLC | Healthcare | 0.8% | $5.3m | 102,000 | -16% | reduced |
| 45 | FBRX FORTE BIOSCIENCES INC | 0.8% | $5.3m | 249,693 | 35% | added | |
| 46 | BIOA BIOAGE LABS INC | 0.7% | $5.2m | 213,671 | 147% | added | |
| 47 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 0.7% | $5.2m | 94,265 | 0% | held |
| 48 | MSLE SATELLOS BIOSCIENCE INC | 0.7% | $5.1m | 652,590 | 33% | added | |
| 49 | PALI PALISADE BIO INC | Healthcare | 0.7% | $4.7m | 2,257,106 | 30% | added |
| 50 | ELDN ELEDON PHARMACEUTICALS INC | 0.7% | $4.7m | 1,191,187 | -33% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.